Burden of cancer attributable to exogenous hormone use in Japan in 2015

Mayo Hirabayashi; Chisato Nagata; Sarah Krull Abe; Norie Sawada; Eiko Saito; Megumi Hori; Kota Katanoda; Tomohiro Matsuda; Manami Inoue; the Cancer PAF Japan Collaborators

doi:10.35772/ghmo.2021.01020

Brief Report

Burden of cancer attributable to exogenous hormone use in Japan in 2015

Mayo Hirabayashi, Chisato Nagata, Sarah Krull Abe, Norie Sawada, Eiko Saito, Megumi Hori, Kota Katanoda, Tomohiro Matsuda, Manami Inoue, the Cancer PAF Japan Collaborators

Author information

Mayo Hirabayashi
Division of Prevention, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.
Chisato Nagata
Department of Epidemiology and Preventive Medicine, Gifu University Graduate School of Medicine, Gifu, Japan.
Sarah Krull Abe
Division of Prevention, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.
Norie Sawada
Division of Cohort Research, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.
Eiko Saito
Division of Cancer Statistics Integration, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan.
Megumi Hori
Division of Cancer Statistics Integration, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan.
Kota Katanoda
Division of Cancer Statistics Integration, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan.
Tomohiro Matsuda
National Cancer Registry Section Center for Cancer Registries Center for Cancer Control and Information Services/Office of International Affairs, Strategic Planning Bureau National Cancer Center, Japan, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.
Manami Inoue
Division of Prevention, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.
Division of Cohort Research, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.
the Cancer PAF Japan Collaborators

Keywords: cancer, exogenous hormone use, oral contraceptives, hormone replacement therapy, population attributable fraction, Japan

JOURNAL FREE ACCESS

2021 Volume 1 Issue 2 Pages 97-101

DOI https://doi.org/10.35772/ghmo.2021.01020

Browse “Advance online publication” version

Details

Abstract

Exogenous female hormone use has not been as popular in Japan as in western populations. Here, we estimated the population-attributable fraction (PAF) of cancers in Japan in 2015 attributed to exogenous female hormone use. We used the most recent prevalence data for oral contraceptives (OC) and hormone replacement therapy (HRT), available from a large-scale population-based cohort study started in 2011-2016. For the purpose of this study, optimal usage of exogenous hormones was considered to be none. PAF was calculated for each age group using a standard formula. Overall, a negligible fraction, 0.4% of cancer incidence and 0.2% of cancer mortality in Japanese women was attributable to exogenous hormone use (OC use and HRT), and 0.2% of cancer incidence and 0.1% of cancer mortality overall when both sexes combined. The relatively low prevalence of exogenous hormone use in Japan compared to Western countries may explain the low fraction of cancer attributable to exogenous hormones among Japanese women.

Corresponding author